Femasys (FEMY) closed at $1.12 on November 17, 2026, down 12.5% from the previous close, on volume of 90,985 shares (30-day average 96,946).
Data as of November 17, 2026.
Femasys GAAP EPS of -$0.53 beats by $0.07, revenue of $0.4M misses by $0.22M
Seeking Alpha News (Fri, 13-Nov 4:17 PM ET)
Globe Newswire (Fri, 13-Nov 4:05 PM ET)
Femasys Appoints John Moorhead to Board of Directors
Globe Newswire (Fri, 30-Oct 9:00 AM ET)
Femasys Partners with SandsRx Pharmacy to Support FemaSeed Fertility Portfolio Launch to OB/GYNs
Globe Newswire (Tue, 20-Oct 9:00 AM ET)
Globe Newswire (Wed, 14-Oct 9:00 AM ET)
Femasys to Exhibit at the ASRM 2026 Scientific Congress & Expo
Globe Newswire (Thu, 8-Oct 9:00 AM ET)
Globe Newswire (Tue, 15-Sep 9:00 AM ET)
Femasys Partners with CapexMD to Expand Patient Access to FemaSeed Fertility Portfolio
Globe Newswire (Wed, 9-Sep 9:00 AM ET)
Globe Newswire (Wed, 26-Aug 9:00 AM ET)
Market Chameleon (Wed, 19-Aug 5:51 AM ET)
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
Femasys trades on the NASDAQ stock market under the symbol FEMY.
As of November 18, 2026, FEMY stock price was flat at $1.12 with 42,080 million shares trading.
FEMY has a beta of 0.91, meaning it tends to be less sensitive to market movements. FEMY has a correlation of 0.02 to the broad based SPY ETF.
FEMY has a market cap of $9.38 million. This is considered a Sub-Micro Cap stock.
Last quarter Femasys reported $404,597 in Revenue and -$.53 earnings per share. This fell short of revenue expectation by $-214,903 and exceeded earnings estimates by $.07.
In the last 3 years, FEMY traded as high as $48.00 and as low as $1.07.
The top ETF exchange traded funds that FEMY belongs to (by Net Assets): VTI, VXF.
FEMY has underperformed the market in the last year with a price return of -93.0% while the SPY ETF gained +11.0%. FEMY has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -48.1% and -20.0%, respectively, while the SPY returned -5.1% and -3.0%, respectively.
FEMY support price is $1.04 and resistance is $1.20 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that FEMY shares will trade within this expected range on the day.